DexCom (NASDAQ:DXCM) Upgraded by Mizuho to “Strong-Buy” Rating

Mizuho upgraded shares of DexCom (NASDAQ:DXCM) to a strong-buy rating in a research report released on Wednesday,Zacks.com reports.

A number of other research firms have also recently issued reports on DXCM. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $99.00.

DexCom Trading Down 2.0 %

Shares of NASDAQ DXCM traded down $1.37 during mid-day trading on Wednesday, reaching $65.93. The company had a trading volume of 365,488 shares, compared to its average volume of 4,162,926. The stock has a market cap of $25.85 billion, a price-to-earnings ratio of 46.11, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom has a 52 week low of $57.52 and a 52 week high of $141.25. The business’s 50-day moving average is $77.35 and its 200-day moving average is $76.62. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts expect that DexCom will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Coldstream Capital Management Inc. lifted its holdings in shares of DexCom by 45.3% during the third quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company’s stock worth $781,000 after purchasing an additional 3,508 shares during the period. Toronto Dominion Bank boosted its holdings in shares of DexCom by 3.1% in the third quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company’s stock valued at $13,711,000 after acquiring an additional 6,227 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of DexCom during the third quarter worth about $1,020,000. Finally, Pine Valley Investments Ltd Liability Co raised its holdings in DexCom by 59.2% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock worth $381,000 after purchasing an additional 2,111 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.